Light chain (AL) amyloidosis results from the deposition of misfolded immunoglobulin light chain produced by a clonal population of B cells or plasma cells into extramedullary tissue. The clinical presentation of patients with AL amyloidosis is heterogeneous, ranging from asymptomatic localized disease not requiring therapy to advanced multisystem involvement. The most common organ systems impacted are the renal and cardiovascular symptoms, with the degree of cardiac involvement at diagnosis being the most significant determinant of long-term prognosis. Recent advances in mechanistic understanding, detection and therapy of AL amyloidosis have high potential to result in improved outcomes for patients.
This Research Topic will present articles covering broad array of topics, including mechanisms of disease in AL amyloidosis, methodologies for diagnosis and early detection in AL amyloidosis, and modern approaches to therapy including novel therapeutics and the optimal use of transplant. The goal is to comprehensively present the latest data informing our understanding of the pathogenesis and modern management of patients with AL amyloidosis.
We welcome authors to submit review and original articles covering the following, and related, subtopics:
-Molecular mechanisms of disease in AL amyloidosis
-Optimizing the early detection of AL amyloidosis
-Modern diagnostic approaches in AL amyloidosis
-Approach to management of end-organ dysfunction in patients with AL amyloidosis, including renal, cardiac, neurologic, and other involvement
-Outcomes research, focusing on the identification of high risk subgroups of patients with AL amyloidosis
-Clinical presentation and management of patients with localized AL amyloidosis
-The potential role of amyloid-degrading agents in the management of patients with AL amyloidosis
-Approaches to frontline therapy of patients with systemic AL amyloidosis
-The role of autologous hematopoietic cellular therapy in managing patients with AL amyloidosis
-The management of relapsed AL amyloidosis, including investigational therapeutics with novel mechanisms of action
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Light chain (AL) amyloidosis results from the deposition of misfolded immunoglobulin light chain produced by a clonal population of B cells or plasma cells into extramedullary tissue. The clinical presentation of patients with AL amyloidosis is heterogeneous, ranging from asymptomatic localized disease not requiring therapy to advanced multisystem involvement. The most common organ systems impacted are the renal and cardiovascular symptoms, with the degree of cardiac involvement at diagnosis being the most significant determinant of long-term prognosis. Recent advances in mechanistic understanding, detection and therapy of AL amyloidosis have high potential to result in improved outcomes for patients.
This Research Topic will present articles covering broad array of topics, including mechanisms of disease in AL amyloidosis, methodologies for diagnosis and early detection in AL amyloidosis, and modern approaches to therapy including novel therapeutics and the optimal use of transplant. The goal is to comprehensively present the latest data informing our understanding of the pathogenesis and modern management of patients with AL amyloidosis.
We welcome authors to submit review and original articles covering the following, and related, subtopics:
-Molecular mechanisms of disease in AL amyloidosis
-Optimizing the early detection of AL amyloidosis
-Modern diagnostic approaches in AL amyloidosis
-Approach to management of end-organ dysfunction in patients with AL amyloidosis, including renal, cardiac, neurologic, and other involvement
-Outcomes research, focusing on the identification of high risk subgroups of patients with AL amyloidosis
-Clinical presentation and management of patients with localized AL amyloidosis
-The potential role of amyloid-degrading agents in the management of patients with AL amyloidosis
-Approaches to frontline therapy of patients with systemic AL amyloidosis
-The role of autologous hematopoietic cellular therapy in managing patients with AL amyloidosis
-The management of relapsed AL amyloidosis, including investigational therapeutics with novel mechanisms of action
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
